AUSTIN, TX, UNITED STATES, September 20, 2025 /EINPresswire.com/ -- According to DataM Intelligence, the next generation antibody therapeutics market size reached US ...
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced ...
US alliance to accelerate next‑generation oral monoclonal antibody therapiesLiège, Belgium, and Roanoke (VA), USA, March 18, 2026 — Bio‑Sourcing SA (‘Bio-Sourcing’) and The Tiny Cargo Company (‘Tiny ...
A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, ...
Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue of ...
BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (HILS) (“Hillstream”, the “Company”) today announced the expansion of its ...
The Monoclonal Antibodies Market has emerged as one of the most transformative sectors within the global biopharmaceutical ...
BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) today announced the expansion of its collaboration with Minotaur Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results